Re:Cognition Health Receives Global Certification for Clinical Excellence at U.S. Clinics

Re:Cognition Health Achieves Global Clinical Site Assessment Recertification

Re:Cognition Health, a premier entity in the exploration and innovation of treatments for Alzheimer’s Disease, has proudly announced the successful renewal of its Global Clinical Site Assessment (GCSA) certification. This prestigious recognition from the International Accrediting Organization for Clinical Research (IAOCR) applies to its four locations across the United States, situated in Fairfax, Virginia; Chicago, Illinois; Houston, Texas; and Fort Worth, Texas.

The GCSA certification represents the pinnacle of quality standards established for clinical research sites globally. It is the sole internationally acknowledged certification developed specifically for trial sites, and Re:Cognition Health made history by becoming the first organization to attain this esteemed certification in both the U.S. and Europe back in 2024.

Currently, a total of 60 clinical trials are being conducted across these four U.S. clinics, focusing on critical issues such as Alzheimer’s Disease, Mild Cognitive Impairment, Bipolar Disorder, and Opioid Use Disorder, among others. This breadth of research underscores the facilities' direct impact on advancing knowledge in these health conditions and potentially enhancing treatment protocols.

Dr. Emer MacSweeney, CEO and Co-Founder of Re:Cognition Health, expressed her pride in the team’s accomplishment, stating, "Our dedication to creating a culture of professionalism and collaboration has been acknowledged at the highest level. We are particularly pleased that the IAOCR assessors highlighted our strong team spirit, transparency, and leadership accessibility, along with our commitment to high engagement in our processes."

The GCSA Standard was developed in collaboration with a Global Advisory Board that comprises senior representatives from various sectors, including global sponsors, clinical research organizations (CROs), public health sites, and government entities, responding to the growing call within the industry for a unified standard evaluating sites from a business and partnership perspective. This certification process is collaborative and thorough, involving comprehensive assessments and gap analyses across seven vital operational areas that define the effective management and execution of high-quality clinical trials.

Mostafa Hassan, the Director of Clinical Trials, USA at Re:Cognition Health, added, "We recognize the immense contribution our participants make to trials that have the power to change and improve the lives of millions. Our commitment is to offer both our participants and their families an unparalleled level of care. This certification embodies far more than merely passing checks; it encapsulates our daily dedication to professionalism, integrity, patient-centered care, and operational excellence."

This certification renewal is not only a testament to Re:Cognition Health's excellence in clinical operation but also serves as a hopeful beacon for future advancements in the medical field. The organization is deeply grateful for the involvement of patients and their families, whose participation is crucial in the search for new and effective treatments.

As Re:Cognition Health continues to champion innovative research and clinical excellence, the ongoing commitment to improving patient care in neurological health remains steadfast, with the aim of delivering earlier diagnoses, advanced therapies, and strategies that safeguard resilience in memory and cognition. Looking ahead, the organization remains excited about its path toward unlocking further discoveries, bringing hope and solutions to those affected by neurological disorders.